

BIOASIS TECHNOLOGIES INC.

3489 CANTERBURY PL. S. SURREY BC V3S 0G8 (604) 542-5059

FOR IMMEDIATE RELEASE

TSX.V BTI

DATE: MAY 27, 2008

JOHN MCKAY JOINS biOASIS TECHNOLOGIES INC.'S ADVISORY BOARD

biOasis Technologies Inc. (the "Company"), (TSX.V: BTI) is pleased to announce the appointment of Mr. John McKay as a member of the Company's Advisory Board. "John has vast expertise in the Pharmaceutical and Biotech fields" says Rob Hutchison, CEO "his industry knowledge and contacts gained through 20 years with SmithKline Beecham and 10 years with Warner Lambert / Parker David and in his current consultancy position, are extremely valuable to biOasis, particularly as we try to identify partners for our technology."

Since late 2000, John established JHM PharmaServices to provide consultancy services in Marketing Strategy, Business Development, Product Assessment and Licensing to various large Pharmaceutical and Bio-Pharmaceutical clients.

Prior to that John was 20 years with SmithKline Beecham, most latterly as Vice President and Director Global Marketing (formerly Strategic Product Development). In this role he was responsible for the worldwide commercial development of major products and the new product pipeline.

During his career he has held General Management and Marketing Management positions in Canada, Brazil, Italy, Latin America and China for SmithKline Beecham and for Warner Lambert. Prior to entering the pharmaceutical industry he had experience in science and new product development positions in the animal agriculture industry.

He holds Science and Business degrees from Mount Allison University and Queens University in Canada.

About the Company

biOasis Technologies Inc. is a Canadian Biotechnology company engaged in the development and commercialization of diagnostics and therapeutics related to neurological diseases. It has extensive and comprehensive intellectual property ("IP") which it obtained from the University of British Columbia. The Company's initial area of focus will be on the utilization of the IP to pursue a biomarker for the diagnosis of Alzheimer's disease. The IP has been corroborated in double blinded and successive multi-site clinical trials.

According to the Centers for Disease Control and Prevention ("CDC"), Alzheimer's disease was listed as the "underlying cause of death" for 65,829 Americans in 2004. It was the seventh leading cause of death for people of all ages and the fifth leading cause of death in people age 65 and older.

To find out more about biOasis Technologies Inc. visit www.bioasis.ca.

"The TSX Venture Exchange has neither approved nor disapproved the contents of this press release."

On Behalf of the Board of Directors

"Robin Hutchison"

Robin Hutchison, Director and CEO